Physiologic clot strength by thromboelastography at extremely low and normal platelet counts in thrombocytopenic pregnant patients

Research and Practice in Thrombosis and Haemostasis 2026 Open access

Read full text
Authors: Kumiko Chino, Yue Qiu, Ximiao Yu, Patricia L. Dalby, C.Tyler Smith, Alexandra Nicholas, Kylie Grady, Amy Monroe, Olivia Jarvis, Grace Lim
DOI: 10.1016/j.rpth.2026.103378
Cited by: 1
References: 22

Abstract

Background: /L safe in low-risk patients, but uncertainty persists at lower levels. Thromboelastography (TEG) measures real-time clot dynamics and may offer physiologic insight beyond standard labs. Modern TEG runs multiple assays in parallel, including citrated kaolin (overall clot strength), citrated rapid TEG (accelerated clotting), and citrated functional fibrinogen (fibrinogen contribution). Its maximum amplitude (MA) reflects final clot strength and may help assess bleeding risk, but its relation to platelet count in pregnancy is not well defined. Objectives: To evaluate the relationship between thromboelastography (TEG) maximum amplitude (MA) and platelet count in pregnant patients with and without thrombocytopenia, and to determine the ability of MA (across CK, CRT, and CFF assays) to discriminate clinically relevant thrombocytopenia (

Fields of Study & Subjects

Trauma Hemostasis Coagulopathy Resuscitation Platelet Disorders and Treatments Blood properties and coagulation

Publication details

Journal / source
Research and Practice in Thrombosis and Haemostasis
Publisher
Elsevier BV
Volume
10
Issue
2
Pages
103378–103378
Publication date
1 February 2026
Language
EN